Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
MENLO PARK, Calif., Nov. 07, 2017 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:
- Stifel 2017 Healthcare Conference in New York at 4:15 p.m. ET on Tuesday, November 14, 2017.
- Piper Jaffray 29th Annual Healthcare Conference in New York at 3:30 p.m. ET on Tuesday, November 28, 2017.
A live audio webcast of each presentation will be available through the Investors section of Geron’s website (www.geron.com) under Events. Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]
